Skip to main content
Premium Trial:

Request an Annual Quote

NimbleGen Raises $12.5 Million in Series D Led by Schott

NEW YORK, April 15 - NimbleGen Systems of Madison, Wis., has raised an additional $12.5 million in a series D round of financing led by European technology giant Schott, the microarray company said today.

 

This brings the total amount that the company has raised to $32.5 million.

 

Schott Nexterion of Mainz, Germany, which is Schott's new life sciences division, led the financing.   ITX of Japan also participated, as did the company's existing venture capital and institutional investors: Skyline Ventures, Venture Investors, Baird Venture Partners, Tactics II Investments LLC, State of Wisconsin Investment Board, and The Wisconsin Alumni Research Foundation.

 

Schott, a $2 billion company that has expertise in manufacture of glass and fiber optics, has been a frequent if low-key exhibitor at recent microarray conferences, and company representatives have expressed an interest in collaborations with companies in the sector.

 

NimbleGen, founded in 2000, has developed technology that uses light-directed chemical synthesis to rapidly build oligo probes on high-density arrays: It boasts of being able to produce an array in a little as three hours.

 

  "The NimbleGen business model fits closely with Schott's strategic plan for investing in innovative microarray technology platforms, said Dirk van den Broek, Schott Nexterion CEO, in a statement. "We are building on our well-established uncoated and coated flat glass products for DNA microarrays and investing in new products and unique microarray technologies."

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.